Bacterial outer membrane vesicle-based cancer nanovaccines
Tumor vaccines, a type of personalized tumor immunotherapy, have developed rapidly in recent decades. These vaccines evoke tumor antigen-specific T cells to achieve immune recognition and killing of tumor cells. Because the immunogenicity of tumor antigens alone is insufficient, immune adjuvants and...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
China Anti-Cancer Association
2022-09-01
|
| Series: | Cancer Biology & Medicine |
| Subjects: | |
| Online Access: | https://www.cancerbiomed.org/content/19/9/1290 |
| _version_ | 1811266000998367232 |
|---|---|
| author | Xiaoyu Gao Qingqing Feng Jing Wang Xiao Zhao |
| author_facet | Xiaoyu Gao Qingqing Feng Jing Wang Xiao Zhao |
| author_sort | Xiaoyu Gao |
| collection | DOAJ |
| description | Tumor vaccines, a type of personalized tumor immunotherapy, have developed rapidly in recent decades. These vaccines evoke tumor antigen-specific T cells to achieve immune recognition and killing of tumor cells. Because the immunogenicity of tumor antigens alone is insufficient, immune adjuvants and nanocarriers are often required to enhance anti-tumor immune responses. At present, vaccine carrier development often integrates nanocarriers and immune adjuvants. Among them, outer membrane vesicles (OMVs) are receiving increasing attention as a delivery platform for tumor vaccines. OMVs are natural nanovesicles derived from Gram-negative bacteria, which have adjuvant function because they contain pathogen associated molecular patterns. Importantly, OMVs can be functionally modified by genetic engineering of bacteria, thus laying a foundation for applications as a delivery platform for tumor nanovaccines. This review summarizes 5 aspects of recent progress in, and future development of, OMV-based tumor nanovaccines: strain selection, heterogeneity, tumor antigen loading, immunogenicity and safety, and mass production of OMVs. |
| first_indexed | 2024-04-12T20:34:12Z |
| format | Article |
| id | doaj.art-aafec467ef95467281b9ebe2dec8bf4f |
| institution | Directory Open Access Journal |
| issn | 2095-3941 |
| language | English |
| last_indexed | 2024-04-12T20:34:12Z |
| publishDate | 2022-09-01 |
| publisher | China Anti-Cancer Association |
| record_format | Article |
| series | Cancer Biology & Medicine |
| spelling | doaj.art-aafec467ef95467281b9ebe2dec8bf4f2022-12-22T03:17:39ZengChina Anti-Cancer AssociationCancer Biology & Medicine2095-39412022-09-011991290130010.20892/j.issn.2095-3941.2022.0452Bacterial outer membrane vesicle-based cancer nanovaccinesXiaoyu Gao0Qingqing Feng1Jing Wang2Xiao Zhao3CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety & CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing 100190, ChinaCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety & CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing 100190, ChinaCenter of Drug Evaluation, National Medical Products Administration, Beijing 100022, ChinaCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety & CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing 100190, ChinaTumor vaccines, a type of personalized tumor immunotherapy, have developed rapidly in recent decades. These vaccines evoke tumor antigen-specific T cells to achieve immune recognition and killing of tumor cells. Because the immunogenicity of tumor antigens alone is insufficient, immune adjuvants and nanocarriers are often required to enhance anti-tumor immune responses. At present, vaccine carrier development often integrates nanocarriers and immune adjuvants. Among them, outer membrane vesicles (OMVs) are receiving increasing attention as a delivery platform for tumor vaccines. OMVs are natural nanovesicles derived from Gram-negative bacteria, which have adjuvant function because they contain pathogen associated molecular patterns. Importantly, OMVs can be functionally modified by genetic engineering of bacteria, thus laying a foundation for applications as a delivery platform for tumor nanovaccines. This review summarizes 5 aspects of recent progress in, and future development of, OMV-based tumor nanovaccines: strain selection, heterogeneity, tumor antigen loading, immunogenicity and safety, and mass production of OMVs.https://www.cancerbiomed.org/content/19/9/1290cancercancer vaccinesouter membrane vesiclesnanocarrierstumor antigen |
| spellingShingle | Xiaoyu Gao Qingqing Feng Jing Wang Xiao Zhao Bacterial outer membrane vesicle-based cancer nanovaccines Cancer Biology & Medicine cancer cancer vaccines outer membrane vesicles nanocarriers tumor antigen |
| title | Bacterial outer membrane vesicle-based cancer nanovaccines |
| title_full | Bacterial outer membrane vesicle-based cancer nanovaccines |
| title_fullStr | Bacterial outer membrane vesicle-based cancer nanovaccines |
| title_full_unstemmed | Bacterial outer membrane vesicle-based cancer nanovaccines |
| title_short | Bacterial outer membrane vesicle-based cancer nanovaccines |
| title_sort | bacterial outer membrane vesicle based cancer nanovaccines |
| topic | cancer cancer vaccines outer membrane vesicles nanocarriers tumor antigen |
| url | https://www.cancerbiomed.org/content/19/9/1290 |
| work_keys_str_mv | AT xiaoyugao bacterialoutermembranevesiclebasedcancernanovaccines AT qingqingfeng bacterialoutermembranevesiclebasedcancernanovaccines AT jingwang bacterialoutermembranevesiclebasedcancernanovaccines AT xiaozhao bacterialoutermembranevesiclebasedcancernanovaccines |